Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...